Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the drugmaker said on Thursday.
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis ...
Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.
Merck's robust Phase 3 pipeline, strong financials, and sustainable dividend make it a compelling investment despite risks like Medicare negotiations and patent expirations. Merck also appears to ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Merck shares tumbled after the drugmaker said it was halting shipments of a top-selling vaccine to China to ...
Merck discussed this decision to stop the HYPERION ... evaluating WINREVAIR versus placebo on top of background therapy, has lost clinical equipoise and should be stopped early,” said Dr.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果